Banff 2011 meeting report: New concepts in antibody-mediated rejection

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 563-570

  Mengel, M ^a,b   Sis, B ^a,b   Haas, M ^c   Colvin, R B ^d   Halloran, P F ^b   Racusen, L C ^e   Solez, K ^a   Cendales, L ^f   Demetris, A J ^g   Drachenberg, C B ^h   Farver, C F ⁱ   Rodriguez, E R ⁱ   Wallace, W D ^j   Glotz, D ^k  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Cedars Sinai Medical Center   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Allograft rejection; allograft transplantation; antibody mediated rejection; Banff classification

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C4D;

ANTIBODY MEDIATED REJECTION; CLASSIFICATION; CONFERENCE PAPER; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; HUMAN; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDICAL SOCIETY; PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY;

CLINICAL TRIALS AS TOPIC; COMPLEMENT C4B; CONGRESSES AS TOPIC; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; PEPTIDE FRAGMENTS; RESEARCH DESIGN;

EID: 84857648352     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03926.x     Document Type: Conference Paper

References (41)

1. Gloor JM, Degoey S, Ploeger N, et al,. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplant 2004; 78: 221-227.
2. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
3. Lefaucheur C, Antoine C, Suberbielle C, Glotz D,. Mastering the risk of HLA antibodies in kidney transplantation: An algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant 2011; 11: 1592-1598.
4. Ravindranath MH, Kaneku H, El-Awar N, Morales-Buenrostro LE, Terasaki PI,. Antibodies to HLA-E in nonalloimmunized males: Pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J Immunol 2010; 185: 1935-1948.
5. Shapiro R, Lunz J, Zeevi A, et al,. 1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection. Clin Transpl 2010; 405-407.
6. Zachary AA, Montgomery RA, Locke JE, Leffell MS,. Proinflammatory events and HLA antibodies. Am J Transplant 2010; 10: 956.
7. Gloor JM, Moore SB, Schneider BA, DeGoey SR, Stegall MD,. The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays. Transplant 2007; 84: 258-264. (Pubitemid 47205761)
8. Gebel HM, Bray RA,. The evolution and clinical impact of human leukocyte antigen technology. Curr Opin Nephrol Hypertens 2010; 19: 598-602.
9. Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D,. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459-466. (Pubitemid 43382131)
10. Montgomery RA, Lonze BE, King KE, et al,. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
11. Lefaucheur C, Nochy D, Andrade J, et al,. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-1107.
12. Gloor J, Stegall MD,. Sensitized renal transplant recipients: Current protocols and future directions. Nat Rev Nephrol 2010; 6: 297-306.
13. Archdeacon P, Chan M, Neuland C, et al,. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896-906.
14. Halloran PF, de Freitas DG, Einecke G, et al,. An integrated view of molecular changes, histopathology, and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223-2230.
15. Einecke G, Halloran PF,. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure: Response to Dr. Loupy et al. Am J Transplant 2009; 9: 2520-2531.
16. El Zoghby ZM, Stegall MD, Lager DJ, et al,. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
17. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure 1. Transplant 2010; 90: 68-74.
18. Hidalgo LG, Sis B, Sellares J, et al,. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10: 1812-1822.
19. Sis B, Jhangri G, Bunnag S, Allanach K, Kaplan B, Halloran PF,. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
20. Loupy A, Suberbielle-Boissel C, Hill GS, et al,. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
21. Loupy A, Hill GS, Suberbielle C, et al,. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56-65.
22. Loupy A, Cazes A, Guillemain R, et al,. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant 2011; 11: 1478-1487.
23. Hill GS, Nochy D, Bruneval P, et al,. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22: 975-983.
24. Sis B, Einecke G, Chang J, et al,. Cluster analysis of lesions in kidney transplant biopsies: Microcirculation changes, tubulointerstitial inflammation, and scarring. Am J Transplant 2010; 10: 421-430.
25. Stegall MD, Diwan T, Raghavaiah S, et al,. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 2011: 2405-2413.
26. Wavamunno MD, O'Connell PJ, Vitalone M, et al,. Transplant glomerulopathy: Ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007; 7: 2757-2768. (Pubitemid 350045771)
27. Cosio FG, Lager DJ, Lorenz EC, Amer H, Gloor JM, Stegall MD,. Significance and implications of capillaritis during acute rejection of kidney allografts. Transplant 2010; 89: 1088-1094.
28. Cosio FG, Gloor JM, Sethi S, Stegall MD,. Transplant glomerulopathy. [Review][25 refs]. Am J Transplant 2008; 8: 492-496.
29. Batal I, Lunz JG, III, Aggarwal N, et al,. A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant 2010; 10: 2442-2452.
30. Baid-Agrawal S, Farris AB, III, Pascual M, et al,. Overlapping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80: 879-885.
31. Sis B, Mengel M, Haas M, et al,. Banff '09 Meeting Report: Antibody mediated graft deterioration and implementation of Banff Working Groups. Am J Transplant 2010; 10: 464-471.
32. Kedainis RL, Koch MJ, Brennan DC, Liapis H,. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant 2009; 9: 812-819.
33. Stegall MD, Park WD, Larson TS, et al,. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11: 698-707.
34. Snanoudj R, Elie C, Rabant M, et al,. Specificity of histological markers of long-term CNI nephrotoxicity in kidney transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11: 2635-2646.
35. Mengel M, Chang J, Kayser D, et al,. The molecular phenotype of six-week protocol biopsies from human renal allografts: Reflections of prior injury but not future course. Am J Transplant 2011; 11: 708-718.
36. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD,. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987-1997.
37. Le TL, Thebault P, Lavault A, et al,. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant 2011; 11: 429-438.
38. Drachenberg CB, Torrealba JR, Nankivell BJ, et al,. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011; 11: 1792-1802.
39. Cendales LC, Kanitakis J, Schneeberger S, et al,. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant 2008; 8: 1396-1400. (Pubitemid 351989486)
40. Berry GJ, Angelini A, Burke MM, et al,. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005-2011). J Heart Lung Transplant 2011; 30: 601-611.
41. Einecke G, Kayser D, Vanslambrouck JM, et al,. Loss of solute carriers in T cell-mediated rejection in mouse and human kidneys: An active epithelial injury-repair response. Am J Transplant 2010; 10: 2241-2251.